Emergent BioSolutions Inc. — Director's Dealing 2022

Mar 4, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2022-03-01

Reporting Person: Fox Jennifer Lynne (EVP, Ext Aff, GC, Corp Sec)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-01	Common Stock	A	7583	—	Acquired	14833	Direct
2022-03-01	Common Stock	A	17794	—	Acquired	32627	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-01	Employee Stock Options (Right to Buy)	$41.38	A	26584	Acquired	2029-02-28	Common Stock (26584.0)	Direct

Footnotes

F1: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.

F2: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest either in three equal annual installments beginning on the day prior to the first anniversary of the date of grant (8,713 shares) or on the day prior to the second anniversary date of the grant (9,063 shares), assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

F3: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.